The South African, Brazil and UK variant covid cases are under close observation.
The South Africa variant has been found in at least 20 other countries, including the UK and nations are responding in kind with travel restrictions and lockdowns.
On Friday, Mr Johnson said there was "some evidence" the UK variant may be associated with "a higher degree of mortality".
However, the UK government's chief scientific officer, Sir Patrick Vallance, said there was "a lot of uncertainty around these numbers" but that early evidence suggested the variant could be about 30% more deadly.
Meanwhile, WHO’s Chief Scientist Dr Soumya explained that 'from the beginning of the year, we've been tracking this virus and we know that it's gone through a lot of changes and there've been variants before.''
''Now this particular time there have been two particular variants that have been reported to WHO'', she added, referring to the UK and one that was identified in South Africa.
In further explanation, she said that ''they do have one change in common, we call it the N501Y mutation. But otherwise, the two are different. And the reason there's a concern is that both of these variants were associated with an increase in the number of cases in both of these countries.''
On the matter of whether they are deadlier or faster spreading she explained, ''scientists have now studied this and have found that these variants do tend to spread faster, they're more transmissible or more infectious. So that's the worrying part. However, so far, they do not seem to cause more severe illness or a higher death rate or any sort of different clinical manifestations.''
Meanwhile, ''they seem to behave pretty much as the previous viruses were behaving and cause a pretty similar kind of disease.''
Vaccine implications
As for the vaccines and whether these vaccines protect us from these variants, Dr Soumya had the following to say:
''Now for SARS-CoV-2 we're still learning, we're still observing and our knowledge is evolving. But at this point in time, most scientists believe that the vaccines that are currently in development and a couple that have been approved should provide protection against this variant and other variants because these vaccines elicit a fairly broad immune response, a host of antibodies and cell-mediated immune responses.''
In other developments
The BBC reported that ''people who have received a Covid-19 vaccine could still pass the virus on to others and should continue following lockdown rules, England's deputy chief medical officer has warned.''
The article notes the Sunday Telegraph piece where Prof Jonathan Van-Tam stressed that scientists "do not yet know the impact of the vaccine on transmission".
He said vaccines offer "hope" but infection rates must come down quickly.
In other news, Mexico’s president is now the latest world leader to become infected with the coronavirus and New Zealand has confirmed the first community coronavirus case in months.
Meanwhile, in the US, Biden officials tried on Sunday to manage public expectations about vaccine distribution, as frustration grows among Americans over long lines, cancelled appointments and other daunting issues.
Dr. Fauci has been trying to reassure the public that the vaccines that are now available would be effective against new variants.
He said that the vaccines could be modified if a particular variant posed a risk, but added that there was no indication yet that modifications would be needed.
Market implications
The market has pulled back from record highs on Wall Street as the risks and unanswered questions about the variant force investors to seek safer havens.
However, at the start of the week, US S&P 500 futures have started out on the front foot and hare higher by 0.34%.
The three main US indexes closed higher for the week, with the Nasdaq up over 4%
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD stays near 1.0800 after upbeat US data
EUR/USD stays under modest bearish pressure and trades near 1.0800 in the American session on Thursday. The data from the US showed that the real GDP growth for the fourth quarter got revised higher to 3.4% from 3.2%, supporting the USD and weighing on the pair.
GBP/USD stays in daily range above 1.2600
GBP/USD fluctuates in a narrow channel above 1.2600 on Thursday. The better-than-expected Initial Jobless Claims data from the US and the upward revision to the Q4 GDP growth helps the USD stay resilient against its rivals and limits the pair's upside.
Gold pulls away from daily highs, holds above $2,200
Gold retreats from daily highs but holds comfortably above $2,200 in the American session on Thursday. The benchmark 10-year US Treasury bond yield stays above 4.2% after upbeat US data and makes it difficult for XAU/USD to preserve its bullish momentum.
XRP price falls to $0.60 support as Ripple ruling doesn’t help Coinbase lawsuit against SEC
XRP programmatic sales ruling by Judge Torres was completely rejected by another US Court that ruled in favor of the SEC in a lawsuit against Coinbase.
Portfolio rebalancing and reflation trades emerge into Q2
Yesterday’s price action pointed at a possible end-of-quarter portfolio rebalancing as the session saw the laggards of the quarter like Apple and Tesla gain, and the stars like Microsoft and Nvidia retreat.